Avant Immunotherapeutics' CholeraGarde(R) Vaccine Development Program Receives Further Funding From The Gates Foundation; New Support Follows Successful Phase 2 Clinical Trials

NEEDHAM, Mass.--(BUSINESS WIRE)--Aug. 2, 2006--AVANT Immunotherapeutics, Inc. (NASDAQ: AVAN) today announced that the International Vaccine Institute ("IVI") has received $21 million in funding from the Bill & Melinda Gates Foundation for a Cholera Vaccine Initiative (CHOVI), which will include conducting further clinical trials of CholeraGarde(R), AVANT's cholera vaccine. Under the direction of John D. Clemens, M.D., IVI plans to conduct Phase 2 and Phase 3 clinical trials of CholeraGarde(R) in Bangladesh and India beginning in 2007. IVI will be purchasing clinical materials produced at AVANT's Fall River, MA manufacturing facility for the trials.

Back to news